European Study of Cerebral Aspergillosis Treated With Isavuconazole

Trial Information
Status: Recruiting
Location: See location...
Study Type: Observational
Summary

Study clinical context Cerebral aspergillosis (CA) is a rare location of invasive aspergillosis (IA), associated with a high morbidity and mortality. Since 2002, voriconazole is the recommended first line treatment of invasive aspergillosis. More recently, isavuconazole appeared to be not less effective than voriconazole in the treatment of filamentous IFI, with a better tolerance profile. The investigators aim to evaluate better the efficacy and the safety of isavuconazole in the treatment of cerebral aspergillosis by a descriptive, multicentric, international retrospective cohort study.

Am I eligible for this trial?
Participation Requirements
Sex:
All
Healthy Volunteers:
No

• Proven or probable cerebral aspergillosis according to the EORTC criteria modified by adding diabetes in the host criteria

• In child or adult

• Treated by isavuconazole at least 7 days

• Diagnosed between March 2017 and June 2020

Where is this trial taking place?
Other Locations
France
Hôpital Necker-Enfants Malades
Recruiting
Paris
Who do I contact about this trial?
Primary
Fanny Lanternier, MD
fanny.lanternier@aphp.fr
01 44 49 52 62
When is this trial taking place?
Start Date: August 1, 2021
Estimated Completion Date: March 1, 2023
How many participants will be in this trial?
Target number of participants: 40
Who are the authors of this trial?

This content was sourced from clinicaltrials.gov

Isavuconazole for the Prevention of SARS-CoV-2-associated Invasive Aspergillosis in Critically-Ill Patients
Who is this study for:Adult patients with COVID-19 Infection
Status:Recruiting
Start Date:March 16, 2021
Study Drug:Isavuconazonium Sulfate
Study Type:Drug
Phase: Phase 3
A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of the Coadministration of SCY-078 With Voriconazole in Patients With Invasive Pulmonary Aspergillosis
Who is this study for:Adult patients with Invasive Pulmonary Aspergillosis
Status:Recruiting
Start Date:January 22, 2019
Study Drug:Ibrexafungerp
Study Type:Drug, Other
Phase: Phase 2
A Randomized Controlled Trial to Compare the Clinical Outcomes With Six Months of Therapy With Oral Itraconazole Versus Oral Voriconazole for Management of Treatment naïve Subjects With Chronic Pulmonary Aspergillosis
Who is this study for:Child to adult patients with Chronic Pulmonary Aspergillosis
Status:Recruiting
Start Date:March 1, 2021
Study Drug:Voriconazole
Study Type:Drug
Phase: Phase 3